General contact

Head Office
Novartis International AG
CH-4002 Basel
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)

Investors

Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland

+41 61 324 79 44

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Featured news

  • 11-Oct-2010
    Novartis continues fight to end leprosy

    Novartis and the World Health Organization (WHO) announced October 11 that they will extend their collaboration to end leprosy.

    Read the article

  • 05-Aug-2010
    New medicines for neglected diseases

    Novartis is pioneering medicines for neglected diseases, with institutes focusing solely on diseases for which research was virtually non-existent.

    Read the article

  • 05-Aug-2010
    Funding future research

    Novartis is leading industry efforts to fill a multi-billion-dollar gap in neglected disease R&D funding.

    Read the article

  • 23-Jun-2010
    Novartis & Citizenship

    See Novartis Chairman Daniel Vasella, M.D., discuss the values and principles of the United Nations Global Compact on its 10th anniversary.

    Read the article

  • 23-Jun-2010
    Living the Global Compact

    In a wide-ranging interview, Klaus Leisinger describes how Novartis embodies the principles of the United Nations Global Compact.

    Read the article

  • 23-Jun-2010
    Environment & Energy

    Keith Saveal, Head of Corporate Health, Safety and Environment & Business Continuity, recounts the evolution of the new UN Environmental Stewardship Strategy.

    Read the article

  • 21-May-2010
    CIBA VISION creates mobile 'app' to train healthcare providers

    Eye care professionals are benefiting from an innovative new iPhone® application offering “anytime, anywhere” access to high-quality educational resources.

    Read the article

  • 23-Apr-2010
    April 25 is World Malaria Day

    On World Malaria Day, April 25, the international community highlights the campaign to provide effective control of this deadly disease.

    Read the article

  • 22-Apr-2010
    Seeking a clearer view of multiple sclerosis

    People with multiple sclerosis (MS) face devastating uncertainty, not knowing how the disease will progress or disrupt their daily lives. But scientists are developing new diagnostic tools to aid treatment and ease the unpredictability for patients.

    Read the article

  • 18-Feb-2010
    Innovating beyond the Vaccine: VaxTrak puts value in the hands of patients and families

    Novartis Vaccines and Diagnostics (NV&D) has developed a way to help parents, families and vaccine consumers track vaccinations using the iPhone®

    Read the article

  • 26-Jan-2010
    New products rejuvenate our pharmaceutical portfolio

    Just as new medicines are improving the lives of patients fighting serious diseases, success in innovation is rejuvenating the portfolio of Novartis. Recently launched products grew to 16% of net sales for the Pharmaceuticals Division in 2009.

    Read the article

  • 22-Jan-2010
    Novartis joins urgent relief efforts for victims of earthquake in Haiti

    Novartis joins urgent relief efforts for victims of earthquake in Haiti offering aid in the form of financial support to relief organizations and donations of essential medicines.

    Read the article

  • 14-Jan-2010
    Legal team helps navigate through economic crisis

    In times of global financial uncertainty, the Novartis legal team takes an innovative approach – serving as both a protective guardian and a proactive partner to the business.

    Read the article

The information in the feature stories on these pages was factually accurate on the date of publication. These feature stories remain on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.